The Drugs Controller General of India (DGCI) has approved the emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, ‘Virafin’ for treating moderate Covid infection in adults.
It is learned that single dose subcutaneous regimen of the antiviral drug will make treatment of Covid-19 disease more convenient.
Zydus has said that when administered early on during Covid, this drug will help patients recover faster and avoid much of the complications.
Virafin will be available on the prescription of a medical specialist for use in hospital/institutional setup.
The company has pointed out that in multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating the disease.
The company has asserted that the drug has also shown efficacy against other viral infections.